Xiaofen Pan

Long-Term Continuation therapy with Nab-Paclitaxel and Bevacizumab ± Anti-PD-1 in Advanced NSCLC: Case Reports and Mechanistic Insights：case report

Background. The role of nab-paclitaxel in non-small cell lung cancer (NSCLC) maintenance therapy remains underexplored, particularly in combination with anti-angiogenic agents and immunotherapy. We present two cases of advanced NSCLC achieving prolonged progression-free survival...